SK88793A3 - Amylin agonising peptides and their using - Google Patents

Amylin agonising peptides and their using Download PDF

Info

Publication number
SK88793A3
SK88793A3 SK887-93A SK88793A SK88793A3 SK 88793 A3 SK88793 A3 SK 88793A3 SK 88793 A SK88793 A SK 88793A SK 88793 A3 SK88793 A3 SK 88793A3
Authority
SK
Slovakia
Prior art keywords
amylin
pro
ser
lys
leu
Prior art date
Application number
SK887-93A
Other languages
English (en)
Slovak (sk)
Inventor
Laura S L Gaeta
Howard Jones
Elisabeth Albrecht
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SK88793A3 publication Critical patent/SK88793A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK887-93A 1991-11-19 1992-11-19 Amylin agonising peptides and their using SK88793A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79426691A 1991-11-19 1991-11-19
PCT/US1992/009842 WO1993010146A1 (fr) 1991-11-19 1992-11-19 Peptides a action agoniste a base d'amyline et utilisations de ces peptides

Publications (1)

Publication Number Publication Date
SK88793A3 true SK88793A3 (en) 1994-12-07

Family

ID=25162163

Family Applications (1)

Application Number Title Priority Date Filing Date
SK887-93A SK88793A3 (en) 1991-11-19 1992-11-19 Amylin agonising peptides and their using

Country Status (17)

Country Link
EP (2) EP0567626B1 (fr)
JP (4) JP2902115B2 (fr)
AT (1) ATE205854T1 (fr)
AU (1) AU714439B2 (fr)
CA (1) CA2100745C (fr)
CZ (1) CZ288029B6 (fr)
DE (1) DE69232064T2 (fr)
DK (1) DK0567626T3 (fr)
ES (1) ES2161697T3 (fr)
FI (1) FI118601B (fr)
GR (1) GR3036794T3 (fr)
HK (1) HK1041891A1 (fr)
MD (1) MD960317A (fr)
NO (2) NO324405B1 (fr)
RU (1) RU2130463C1 (fr)
SK (1) SK88793A3 (fr)
WO (1) WO1993010146A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
SK31496A3 (en) 1993-09-07 1998-06-03 Amylin Pharmaceuticals Inc Use of amylin, amylin agonists and amylin antagonists for regulating gastrointestinal motility
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
DE69840106D1 (de) * 1998-01-09 2008-11-20 Amylin Pharmaceuticals Inc Formulierungen für amylin peptidagonisten mit insulin
GB0128583D0 (en) 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
WO2004037168A2 (fr) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Traitement de la pancreatite avec de l'amyline
EP1603944A1 (fr) * 2003-03-18 2005-12-14 Applied Research Systems ARS Holding N.V. Inhibiteurs de l'aggregation de l'amyline et leur utilisation
KR20070083815A (ko) * 2004-10-26 2007-08-24 론자 아게 고체상 합성에서 ｓ-알킬-술페닐 보호기
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
JP4926069B2 (ja) 2004-11-01 2012-05-09 アミリン・ファーマシューティカルズ，インコーポレイテッド 肥満ならびに肥満関連疾患および障害の治療方法
US7879794B2 (en) * 2005-03-31 2011-02-01 Amylin Pharmaceuticals, Inc. Methods for controlling binge eating disorders
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
WO2008097536A2 (fr) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions et méthodes de traitement de maladies et troubles psychiatriques
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
RU2537181C2 (ru) 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
US10072060B2 (en) 2014-05-02 2018-09-11 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
MX2017011182A (es) * 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
WO2018144671A1 (fr) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Polypeptides à îlots amyloïdes mutants présentant une solubilité améliorée et leurs procédés d'utilisation
KR102130354B1 (ko) * 2019-08-14 2020-07-06 엘아이지넥스원 주식회사 코어 제거용 이형장치
KR20240099373A (ko) 2022-05-30 2024-06-28 질랜드 파마 에이/에스 아밀린 유사체의 액체 제제
WO2024061919A1 (fr) 2022-09-19 2024-03-28 Zealand Pharma A/S Polythérapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
WO1989006135A1 (fr) * 1988-01-11 1989-07-13 Amylin Corporation Traitement du diabete sucre du type 2
ATE128032T1 (de) * 1989-07-10 1995-10-15 Amylin Pharmaceuticals Inc Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (fr) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Preparation synthetique d'amyline et d'analogues d'amyline

Also Published As

Publication number Publication date
JP2006213716A (ja) 2006-08-17
FI933252A (fi) 1993-08-23
JP2902115B2 (ja) 1999-06-07
EP1162207A1 (fr) 2001-12-12
GR3036794T3 (en) 2002-01-31
NO20073265L (no) 1993-09-17
AU714439B2 (en) 2000-01-06
HK1041891A1 (zh) 2002-07-26
FI933252A0 (fi) 1993-07-16
EP0567626B1 (fr) 2001-09-19
NO932603L (no) 1993-09-17
WO1993010146A1 (fr) 1993-05-27
JP4018116B2 (ja) 2007-12-05
RU2130463C1 (ru) 1999-05-20
JPH11152299A (ja) 1999-06-08
CZ168993A3 (en) 1994-04-13
NO324405B1 (no) 2007-10-08
JPH06504794A (ja) 1994-06-02
CA2100745A1 (fr) 1993-05-20
JP2003238594A (ja) 2003-08-27
DE69232064D1 (de) 2001-10-25
DK0567626T3 (da) 2001-12-17
AU673147B2 (en) 1996-10-31
ES2161697T3 (es) 2001-12-16
AU1245697A (en) 1997-03-27
MD960317A (ro) 1998-05-31
NO932603D0 (no) 1993-07-19
EP0567626A1 (fr) 1993-11-03
CZ288029B6 (cs) 2001-04-11
FI118601B (fi) 2008-01-15
CA2100745C (fr) 2007-07-31
ATE205854T1 (de) 2001-10-15
DE69232064T2 (de) 2002-03-28
AU3075392A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
SK88793A3 (en) Amylin agonising peptides and their using
US7271238B2 (en) Amylin agonist peptides and uses therefor
AU2017216533B2 (en) Improved peptide pharmaceuticals
AU766545B2 (en) Novel anti-diabetic peptides
CA2891929C (fr) Agents pharmaceutiques peptidiques ameliores
JP2022172128A (ja) インスリン抵抗性のための改善されたペプチド医薬品
CN103732617A (zh) 用于胰岛素抵抗的改进的肽医药
JP2003501361A (ja) 妊娠糖尿病の治療のためのエキセンジンおよびそのアゴニストの使用
JP2003522721A (ja) 新規なエキセンジンアゴニスト化合物
JP2001513512A (ja) 新規なエキセンディン作動剤化合物
SK88893A3 (en) Novel amylin antagonist peptides and uses therefor
EA038073B1 (ru) Ацилированное инсулиновое соединение
JP2002522355A (ja) 新規な混合アミリン活性化合物
AU669636B2 (en) Amylin antagonists and agonists
AU673147C (en) Amylin agonist peptides and uses therefor
KR20230106481A (ko) 지속형 지방산-펩타이드 유도체 및 이의 용도